Pay in 4 interest-free payments of $5.53 Learn more
Ships within 48 hours · Estimated delivery Sep 12 - Sep 17
Early data are promising: retatrutide, a leading candidate in this class, produced 24.2% average weight loss at 48 weeks in a Phase 2 trial, exceeding results seen with current medications
It plays a significant role in protecting gastrointestinal tract lining from damage and promotes healing and blood vessel growth
Week 1 The starting dose is intentionally low
May produce greater weight loss More expensive Semaglutide vs Rybelsus Rybelsus is an oral version
Clinical trials are limited but preclinical data support its broad therapeutic potential
5 stars isnt enough I wish I could give her 10
US$ 28.54
US$ 27.51
US$ 28.18
